Transcatheter edge-to-edge repair reduced the rate of cardiovascular death or heart failure hospitalization by 36% (HR 0.64, 95% CI 0.48–0.85, p=0.002) compared to medical therapy in patients with symptomatic secondary mitral regurgitation.
This comprehensive review highlights the anatomical and technical complexities of mitral valve repair, emphasizing the need for personalized surgical and transcatheter approaches to optimize patient outcomes.
Effect estimate: HR 0.64 (95% CI 0.48–0.85)
Absolute Event Rate: 37% vs 58.9%
p-value: p=0.002
Mitral valve repair has emerged as the gold standard treatment for mitral regurgitation, offering superior long-term outcomes compared with valve replacement. However, the repair process remains one of the most technically demanding and clinically complex procedures in cardiac surgery. Moreover, despite significant advances in surgical techniques, imaging modalities, and transcatheter interventions, the complexity of mitral valve anatomy and pathophysiology continues to present formidable obstacles to clinicians worldwide. The complexity of mitral repair encompasses both technical surgical skills and a sophisticated understanding of valve mechanics, advanced interpretation of imaging, and multidisciplinary team coordination. Thus, as we advance into an era of precision medicine and personalized cardiac interventions, addressing these difficulties becomes increasingly critical for optimizing patient outcomes and advancing the field of structural heart disease. This comprehensive review describes the multifaceted challenges encountered in contemporary mitral valve repair, including anatomical complexity, pathological heterogeneity, technical limitations, patient selection difficulties, and concerns about long-term durability. Moreover, we analyze the outcomes of various repair strategies, discuss the limitations of current approaches, and explore future directions in this rapidly evolving field. This review provides a strategic vision to advance personalized mitral valve interventions and optimize patient outcomes by bridging current limitations and actionable priorities for the future.
Takaki et al. (Wed,) conducted a review in Patients with symptomatic severe mitral regurgitation (degenerative or functional) suitable for mitral valve intervention. Transcatheter edge-to-edge repair (TEER) with MitraClip device vs. Surgical repair/replacement or guideline-directed medical therapy (GDMT) alone was evaluated on Composite of all-cause death, repeat mitral surgery, or ≥ moderate mitral regurgitation or heart failure hospitalization as defined in trials (HR 0.64, 95% CI 0.48–0.85, p=0.002). Transcatheter edge-to-edge repair reduced the rate of cardiovascular death or heart failure hospitalization by 36% (HR 0.64, 95% CI 0.48–0.85, p=0.002) compared to medical therapy in patients with symptomatic secondary mitral regurgitation.